- Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s JournaxLatigo Biotherapeutics is preparing to go public in order to bankroll the development of its clinical-stage pipeline of non-opioid pain management drugs.Fierce Biotech · 9d ago↗ source
- Geopolitics ‘chills’ British biotech IPO plans, despite $2B in Q2 VC fundsGeopolitical uncertainty has continued to “chill” IPO sentiment among British biotechs, an industry leader has told Fierce, even as the sector saw second-quarter venture capital funding reach a fiv…Fierce Biotech · 9d ago↗ source
- Abbott hit by cyberattack on cancer diagnostics, LabCentral portal businessesAbbott has been struck by several cyberattacks which targeted the medtech giant’s cancer diagnostics and LabCentral businesses.